Clinical Trials Using Sorafenib Tosylate

Clinical trials are research studies that involve people. The clinical trials on this list are studying Sorafenib Tosylate. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-19 of 19
  • Sorafenib with or without Everolimus in Treating Patients with Advanced, Radioactive Iodine Refractory Thyroid Cancer

    This randomized phase II trial studies the effects, good and bad, of using everolimus along with sorafenib versus sorafenib alone in treating patients with thyroid cancer that has spread to other places in the body or cannot be removed by surgery and has not responded to treatment with radioactive iodine. Sorafenib and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The addition of everolimus to sorafenib may cause more shrinkage of thyroid cancer and may prevent it from growing but it could also cause more side effects than sorafenib alone. It is not yet known whether this treatment with sorafenib and everolimus is better, the same, or worse than sorafenib alone.
    Location: 21 locations

  • Sorafenib Tosylate with or without Stereotactic Body Radiation Therapy in Treating Patients with Liver Cancer

    This randomized phase III trial studies sorafenib tosylate and stereotactic body radiation therapy to see how well they work compared to sorafenib tosylate alone in treating patients with liver cancer. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. It is not yet known whether giving sorafenib tosylate together with stereotactic body radiation therapy is more effective than sorafenib tosylate alone in treating liver cancer.
    Location: 30 locations

  • Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

    This is a randomized, open-label, multi-center, global, Phase III study to assess the efficacy and safety of durvalumab plus tremelimumab combination therapy and durvalumab monotherapy versus sorafenib in the treatment of patients with no prior systemic therapy for unresectable HCC. The patients cannot be eligible for locoregional therapy.
    Location: 15 locations

  • Azacitidine or Decitabine in Epigenetic Priming in Patients with Newly Diagnosed Acute Myeloid Leukemia

    This randomized phase II trial studies how well azacitidine or decitabine work in epigenetic priming in patients with newly diagnosed acute myeloid leukemia. Azacitidine and decitabine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
    Location: 11 locations

  • Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone

    This is a randomized Phase 3 study to determine whether treatment with vaccinia virus based immunotherapy (Pexa-Vec) followed by sorafenib increases survival compared to treatment with sorafenib in patients with advanced hepatocellular carcinoma who have not received prior systemic therapy.
    Location: 11 locations

  • Navitoclax and Sorafenib Tosylate in Treating Patients with Relapsed or Refractory Solid Tumors

    This phase I trial studies the side effects and the best dose of navitoclax when given together with sorafenib tosylate in treating patients with solid tumors that have returned (relapsed) or do not respond to treatment (refractory). Navitoclax and sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 8 locations

  • Sorafenib Tosylate and Whole Brain Radiation Therapy in Treating Patients with Brain Metastases from Breast Cancer

    This phase I trial studies the side effects and best dose of sorafenib tosylate when given together with whole brain radiation therapy in treating patients with breast cancer that has spread to the brain. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for tumor growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving sorafenib tosylate and whole-brain radiation therapy together may kill more tumor cells.
    Location: 6 locations

  • Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

    A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma.
    Location: 4 locations

  • Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy

    This Phase 3 study evaluates the safety and efficacy of cabozantinib in combination with atezolizumab versus the standard of care sorafenib in adults with advanced hepatocellular carcinoma (HCC) who have not received previous systemic anticancer therapy. A single-agent cabozantinib arm will be enrolled in which subjects receive single agent cabozantinib in order to determine its contribution to the overall safety and efficacy of the combination with atezolizumab.
    Location: 4 locations

  • Sorafenib Tosylate and Pembrolizumab in Treating Patients with Advanced or Metastatic Liver Cancer

    This phase Ib / II trial studies how well sorafenib tosylate and pembrolizumab work in treating patients with liver cancer that has spread to other parts of the body. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving sorafenib tosylate and pembrolizumab may work better in treating patients with liver cancer.
    Location: 2 locations

  • Risk Adapted Focal Proton Beam Radiation and / or Surgery in Participants with Low, Intermediate, and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

    This phase II trial studies how well chemotherapy, surgery, and radiation therapy work in treating patients with newly diagnosed rhabdomyosarcoma that has spread to other parts of the body. Drugs used in chemotherapy, such as vincristine sulfate, dactinomycin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving combination chemotherapy and radiation therapy after surgery may kill any tumor cells that remain after surgery.
    Location: 2 locations

  • Sorafenib Tosylate and Hydroxychloroquine Sulfate in Treating Patients with Advanced or Metastatic Liver Cancer

    This phase II trial studies how well sorafenib tosylate and hydroxychloroquine sulfate work in treating patients with liver cancer that has spread to other parts of the body. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hydroxychloroquine sulfate may increase the effectiveness of sorafenib tosylate. Giving sorafenib tosylate and hydroxychloroquine may work better in treating patients with liver cancer.
    Location: Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas

  • Personalized Kinase Inhibitor Therapy Combined with Chemotherapy in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

    This phase IB trial studies the feasibility of using a functional laboratory based study to determine how well the test can be used to select personalized kinase inhibitor therapy in combination with standard chemotherapy in treating patients with newly diagnosed acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). It also evaluates safety and potential efficacy. Kinase inhibitor is a type of substance that blocks an enzyme called a kinase. Human cells have many different kinase enzymes, and they help control important cell functions. Certain kinases are more active in some types of cancer cells and blocking them may help keep the cancer cells from growing. Testing samples of blood from patients with AML and ALL in the laboratory with kinase inhibitors may help determine which kinase inhibitor has more activity against cancer cells and which one should be combined with standard of care chemotherapy. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving a personalized kinase inhibitor therapy combined with standard chemotherapy may be a better treatment for AML and ALL.
    Location: OHSU Knight Cancer Institute, Portland, Oregon

  • Sorafenib Tosylate and Irinotecan Hydrochloride in Treating Pediatric Patients with Recurrent or Refractory Solid Tumors

    This phase II trial studies how well sorafenib tosylate and irinotecan hydrochloride work in treating pediatric patients with solid tumors that have returned after a period of improvement or have not responded to previous treatment. Sorafenib tosylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving sorafenib tosylate and irinotecan hydrochloride may work better in treating pediatric patients with recurrent or refractory solid tumors.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri

  • Filgrastim, Cladribine, Cytarabine, and Mitoxantrone with Sorafenib Tosylate in Treating Patients with Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

    This phase I / II trial studies the side effects and best dose of filgrastim (granulocyte colony-stimulating factor [G-CSF]), cladribine, cytarabine, and mitoxantrone hydrochloride, when given together with sorafenib tosylate and to see how well they work in treating patients with newly-diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome (likely to be more aggressive). Drugs used in chemotherapy, such as filgrastim, cladribine, cytarabine, and mitoxantrone hydrochloride work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Sorafenib tosylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving filgrastim, cladribine, cytarabine, and mitoxantrone hydrochloride together with sorafenib tosylate may kill more cancer cells.
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

  • Sorafenib Tosylate, Vorinostat, Gemcitabine Hydrochloride, and Radiation Therapy in Treating Patients with Pancreatic Cancer

    This phase I trial studies the side effects and best dose of sorafenib tosylate and vorinostat when given together with gemcitabine hydrochloride and radiation therapy in treating patients with pancreatic cancer. Sorafenib tosylate and vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving sorafenib tosylate, vorinostat, gemcitabine hydrochloride, and radiation therapy may be a better treatment for pancreatic cancer.
    Location: Virginia Commonwealth University / Massey Cancer Center, Richmond, Virginia

  • Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients with Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia

    This phase II trial studies how well clofarabine, idarubicin, cytarabine, vincristine sulfate, and dexamethasone work in treating patients with mixed phenotype acute leukemia that is newly diagnosed or has returned after a period of improvement (relapsed). Drugs used in chemotherapy, such as clofarabine, idarubicin, cytarabine, vincristine sulfate, and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Sorafenib Tosylate, Valproic Acid, and Sildenafil Citrate in Treating Patients with Recurrent or Progressive High-Grade Glioma

    This phase II trial studies how well sorafenib tosylate, valproic acid, and sildenafil citrate work in treating patients with high-grade glioma that has returned (recurrent) or is growing, spreading, or getting worse (progressive). Sorafenib tosylate and valproic acid may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sildenafil citrate may help with getting sorafenib tosylate into the brain tumor. Giving sorafenib tosylate, valproic acid, and sildenafil citrate may work better in treating patients with high-grade glioma.
    Location: Virginia Commonwealth University / Massey Cancer Center, Richmond, Virginia

  • ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Liver Cancer

    The purpose of this study is to evaluate the efficacy and safety of ET 140202 -T cell combined With TAE or Sorafenib in the treatment of liver cancer
    Location: UC Irvine Health / Chao Family Comprehensive Cancer Center, Orange, California